The FDA announced on May 6, 2025, that it intends to expand its use of unannounced inspections at foreign manufacturing facilities. Here are key considerations and actions to take in order to be prepared.
- Unlocking Value In Biopharma Operations: A C-Suite Call To Action
- Audit Trail Compliance And What To Look For In Mitigation Software
- The New Clinical Packaging Paradigm: Differentiation And Decentralization
- Process Validation: Optimizing Operational Excellence In Pharma And Medical Devices
- Cleaning Process Capability: Risk-Based Cleaning Process Performance Qualification
- AI-Assisted QMS: Bridging ISO/IEC 42001:2023 And ICH Q10 For Pharmaceutical Excellence
- Navigating FDA Regulatory Changes: Policy Shifts, Deregulation, Restructuring, And Future Oversight
GUEST COLUMNISTS
-
Unlocking Value In Biopharma Operations: A C-Suite Call To Action
Operational readiness will separate the leaders from the laggards, whether you lead a pharma/biotech innovator, CDMO, or a combination of both.
-
Audit Trail Compliance And What To Look For In Mitigation Software
In the pharma/biotech and medical device industries, the audit trail is important to have for accountability, data integrity, repeatability to create an event for investigation, and regulatory compliance.
-
The New Clinical Packaging Paradigm: Differentiation And Decentralization
The rapid evolution toward flexible, decentralized clinical supply models is placing unprecedented strain on traditional clinical packaging organizations. Can traditional models adapt fast enough to stay viable?
-
Process Validation: Optimizing Operational Excellence In Pharma And Medical Devices
Process validation is often viewed as a costly regulatory formality. However, it is actually a strategic investment that, when integrated into business planning, delivers measurable outcomes in productivity, compliance, speed-to-market, and profitability.
-
Cleaning Process Capability: Risk-Based Cleaning Process Performance Qualification
A cleaning validation professional must know how many process performance qualification runs are necessary. Here's how to go about demonstrating this with a high degree of assurance while minimizing the number of qualification runs.
-
AI-Assisted QMS: Bridging ISO/IEC 42001:2023 And ICH Q10 For Pharmaceutical Excellence
Integrating AI into quality management systems (QMS) can be a transformative opportunity to enhance quality assurance, improve compliance, and enable proactive risk management.
-
Navigating FDA Regulatory Changes: Policy Shifts, Deregulation, Restructuring, And Future Oversight
Recent shifts within the U.S. FDA reflect an increasingly complex tension between scientific rigor and accelerating political and economic pressures. Here are the newest developments and emerging focal points.
BIOSIMILAR WHITE PAPERS
-
Eliminating USP <88> In Vivo Animal Bioreactivity Testing For Polymer Characterization
There has been growing awareness about the environmental and ethical implications of plastics used in bioprocessing. The time for a shift to well-studied, proven in vitro cytotoxicity testing is now.
-
The Role Of Extractables Data In The Adoption Of Single-Use Systems8/29/2024
Explore guidance for evaluating single-use systems for extractables and leachables, and learn how supplier-provided single-use system extractables data can save both time and resources.
-
A Supplier-Manufacturer Approach To Mitigating Nitrosamine Risk10/10/2024
Learn about how nitrosamines are formed, their prevalence and chemical precursors in pharmaceuticals, techniques for quantification, and approaches for managing nitrite impurities.
-
Five Essentials For Accurate Oligonucleotide Chemistry3/4/2024
Explore five key areas in oligonucleotide chemistry where improvements will have a huge influence on your synthesis quality.
-
Considerations For Developing The Recirculation/Perfusion Process6/6/2024
Learn about the recirculation and perfusion processes made possible by single-use, fixed-bed bioreactors designed for scaling up adherent cell culture processes.
-
Perfusion Cell Line Development For Intensified Processes5/5/2025
The biopharmaceutical industry is transforming by shifting to continuous and intensified upstream bioprocesses, which are driven by evolving demands. Discover the key goals and innovations shaping this transition for modern healthcare.
BIOSIMILAR APP NOTES & CASE STUDIES
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS

The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Celltrion USA Announces U.S. Launch Of Denosumab Biosimilars, STOBOCLO® And OSENVELT® (denosumab-bmwo)
- Advancing Bone Health: European Commission Approves Biocon Biologics' Denosumab Biosimilars
- Sunshine Biopharma Launches NIOPEG(R) Into $10B Biologics Market
- mAbxience Announces European Commission Approval Of Denosumab Biosimilars
- Apotex Receives Health Canada Approval For Aflivu™, A Biosimilar To Eylea®, Available In Pre-Filled Syringe And Vial Formats
- Fresenius Expands Biosimilars Portfolio With The Launch Of Denosumab Biosimilars In The US
- Alvotech And Advanz Pharma Enter Into European Supply And Commercialization Agreement For Biosimilar Candidate To Cimzia® (certolizumab pegol)
- Bio Usawa Biotechnology And Bioeq AG Partner To Create Widespread Access To Vision-Saving Medicine Across Sub-Saharan Africa
NEWSLETTER ARCHIVE
- 07.10.25 -- Take a look at our useful PUPSIT overview and implementation resources.
- 07.10.25 -- Transitioning From Research To Commercialization: A Roadmap
- 07.03.25 -- How APBio Builds Multispecific Analytical Target Profiles
- 06.26.25 -- Formulation Is Key For Y-mAbs' Self-Assembling Antibody
- 06.19.25 -- Your helping hand in filtration for high concentration drugs.